Cigna earnings beat by $0.04, revenue topped estimates
EDMONTON - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), whose stock has seen a -9% return over the past week but maintains a positive 16% return over six months, issued a reminder to shareholders about its upcoming annual general and special meeting scheduled for Friday, August 8, 2025, at 1:00 p.m. Eastern Time.
The virtual meeting will be held via live webcast, with the proxy voting deadline set for Wednesday, August 6, 2025, at 1:00 p.m. Eastern Time.
The company’s board of directors recommends that shareholders vote in favor of all director nominees and proposed resolutions. Aurora emphasized that all shareholder votes matter regardless of the number of shares owned.
Shareholders seeking assistance with voting can contact Laurel Hill Advisory Group, Aurora’s proxy solicitation agent, by phone at 1-877-452-7184 or by email.
Aurora Cannabis describes itself as a Canada-based global medical cannabis company serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand. The company’s brand portfolio includes Drift, San Rafael ’71, Daily Special, and several others in the adult-use segment, while its medical cannabis brands include MedReleaf, CanniMed, and Aurora.
The company also noted its controlling interest in Bevo Farms Ltd., which it identified as North America’s leading supplier of propagated agricultural plants.
Meeting materials are available on Aurora’s website and under its profile on SEDAR+, according to the press release statement.
In other recent news, Aurora Cannabis Inc. has announced the details for its upcoming annual general and special meeting of shareholders, scheduled for August 8, 2025. The meeting will be held virtually, allowing shareholders from various locations to participate. Aurora Cannabis has also expanded its medical cannabis compassionate pricing program in Canada by increasing the yearly income threshold from $40,000 to $60,000 CAD, aiming to make medical cannabis more accessible to a broader range of patients. Additionally, the company has denied reports of a potential acquisition of MedLeaf Therapeutics, clarifying that no discussions or agreements have taken place. In Australia, Aurora has introduced two new high-potency medical cannabis strains under its IndiMed brand, which are available through MedReleaf Australia. The new strains, IndiMed TEMPO 22 | Lemon Laser and IndiMed TEMPO 22 | Pickled Petrol, aim to provide more treatment options for patients. Furthermore, Aurora Cannabis has filed a Form 6-K report with the U.S. Securities and Exchange Commission for June 2025, detailing the company’s activities for the month.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.